Showing results (41-50 of 64) with videos related to

Sort By:
Pageof 7
Journal of Clinical Medicine|November 11, 2022
Tailored Direct Oral Anticoagulation in Patients with Atrial Fibrillation: The Future of Oral Anticoagulation?Matej Samoš, Tomáš Bolek, Lucia Stančiaková, et al.
Pharmaceuticals (Basel, Switzerland)|March 28, 2024
Application of Liquid Chromatography Coupled to Mass Spectrometry for Direct Estimation of the Total Levels of Adenosine and Its Catabolites in Human BloodJakub Šofranko, Peter Mitro, Zora Lazúrová, et al.
Clinical Nutrition ESPEN|December 20, 2025
Effect of semaglutide with metformin for weight loss and fertility in polycystic ovary syndrome (PCOS) patients with obesity: A pilot prospective studyTomáš Bolek, Petra Turňová, Svetlana Janošova, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|March 15, 2018
Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot studyMatej Samoš, Tomáš Bolek, Lucia Stančiaková, et al.
Diabetes Research and Clinical Practice|November 28, 2017
Does type 2 diabetes affect the on-treatment levels of direct oral anticoagulants in patients with atrial fibrillation?Matej Samoš, Tomáš Bolek, Lucia Stančiaková, et al.
The American Journal of Emergency Medicine|February 25, 2014
Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosisMatej Samoš, Radoslava Šimonová, Frantisek Kovář, et al.
Diagnostics (Basel, Switzerland)|July 13, 2024
Left Ventricular and Atrial Deformation in Patients with Acute Decompensated Heart Failure: A Pilot StudyJakub Jurica, Martin Jozef Péč, Marek Cingel, et al.
Journal of Clinical Medicine|March 11, 2023
COVID-19 and the Response to Antiplatelet TherapyTomáš Bolek, Matej Samoš, Jakub Jurica, et al.
Case Reports in Hematology|September 5, 2022
SARS-CoV-2 Infection-Associated Aortic Thrombosis Treated with Oral Factor Xa InhibitionAlena Strýčková, Jakub Benko, Martin Jozef Péč, et al.
Scientific Reports|June 3, 2026
Real-world use of submaximal doses of long-acting GLP-1 receptor agonist semaglutide in patients with obesity: a prospective observational studyZuzana Miertová, Patrik Lecký, Boris Focko, et al.
Pageof 7